JNCCN 360, the Source for Tumor-Specific News and Treatment Updates, Available Now
Launched during the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™, JNCCN360.org is the latest resource from the Journal of the National Comprehensive Cancer Network (JNCCN). Currently available for breast and non–small cell lung cancers, JNCCN 360 is a network of tumor-specific microsites that provides users with carefully curated content tailored specifically to NCCN’s audience.
“JNCCN and Harborside Press are proud to launch JNCCN 360. We have and will continue to work closely with editors and members of the expert NCCN Guidelines panels to identify and deliver the most relevant information and news to our users to provide a view of the state of cancer care delivery from every angle,” said Conor Lynch, Executive Editor, Harborside Press—publisher of JNCCN.
Tumor-specific content hosted on JNCCN 360 includes, but is not limited to, video discussions with clinical leaders, medical literature summaries, news briefs, patient resources, and JNCCN Spotlights. A new clinical resource published specifically for JNCCN 360, JNCCN Spotlights discuss the safe and effective use of single-agent therapies within the NCCN Guidelines® and the NCCN Drugs & Biologics Compendium (NCCN Compendium®). JNCCN Spotlights will provide clinical recommendations from practitioners who have hands-on experience with a particular therapy, including principal investigators, NCCN Guidelines® panel members, and other thought leaders in oncology.
JNCCN 360 microsites for B-cell lymphoma, colorectal cancer, kidney cancer, myeloma, and soft-tissue sarcoma are expected to launch soon. ■